Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2337485
Max Phase: Preclinical
Molecular Formula: C28H46N3O4P
Molecular Weight: 519.67
Molecule Type: Small molecule
Associated Items:
ID: ALA2337485
Max Phase: Preclinical
Molecular Formula: C28H46N3O4P
Molecular Weight: 519.67
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCCP(=O)(O)C1=CC[C@H](NC(=O)CCCCCCCCCCNC(=O)c2ccccc2NC)C1
Standard InChI: InChI=1S/C28H46N3O4P/c1-3-4-21-36(34,35)24-19-18-23(22-24)31-27(32)17-11-9-7-5-6-8-10-14-20-30-28(33)25-15-12-13-16-26(25)29-2/h12-13,15-16,19,23,29H,3-11,14,17-18,20-22H2,1-2H3,(H,30,33)(H,31,32)(H,34,35)/t23-/m0/s1
Standard InChI Key: YTZPTLZTLYLCJC-QHCPKHFHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 519.67 | Molecular Weight (Monoisotopic): 519.3226 | AlogP: 6.20 | #Rotatable Bonds: 18 |
Polar Surface Area: 107.53 | Molecular Species: ACID | HBA: 4 | HBD: 4 |
#RO5 Violations: 2 | HBA (Lipinski): 7 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 3.65 | CX Basic pKa: 2.70 | CX LogP: 4.09 | CX LogD: 2.00 |
Aromatic Rings: 1 | Heavy Atoms: 36 | QED Weighted: 0.14 | Np Likeness Score: -0.43 |
1. Gavande N, Kim HL, Doddareddy MR, Johnston GA, Chebib M, Hanrahan JR.. (2013) Design, Synthesis, and Pharmacological Evaluation of Fluorescent and Biotinylated Antagonists of ρ1 GABAC Receptors., 4 (4): [PMID:24900684] [10.1021/ml300476v] |
Source(1):